Pamidronate: An unrecognized problem in gastrointestinal tolerability

E. G. Lufkin, R. Argueta, M. D. Whitaker, A. L. Cameron, V. H. Wong, K. S. Egan, W. M. O'Fallon, B. L. Riggs

Research output: Contribution to journalArticle

160 Citations (Scopus)

Abstract

Pamidronate (aminohydroxypropylidine bisphosphonate, APD) is an effective agent for treatment of Paget's disease of bone, and it has also been thought to be effective for treatment of osteoporosis. We desired to study a newer, time-release preparation of pamidronate, and carried out a placebo-controlled, double-masked study of postmenopausal osteoporosis. The original formulation was in a rapidly dissolving gelatin capsule. We encountered four episodes of esophagitis in 49 enrolled patients. We therefore discontinued treatment with this preparation and later began the study again using a standard tablet preparation. We encountered an additional case of erosive esophagitis in 1 patient of 40 receiving this tablet preparation. No patient was receiving concomitant medication which could cause esophagitis. Two of the patients gave a past history of hiatal hernia and 1 gave a history of gastric ulcer 27 years previously. The diagnosis of esophagitis was confirmed in all cases by endoscopy. Healing of the esophagitis promptly ensued after discontinuation of the pamidronate and the use of antacid medication.

Original languageEnglish (US)
Pages (from-to)320-322
Number of pages3
JournalOsteoporosis International
Volume4
Issue number6
DOIs
StatePublished - Nov 1994

Fingerprint

pamidronate
Esophagitis
Tablets
Osteitis Deformans
Antacids
Postmenopausal Osteoporosis
Hiatal Hernia
Diphosphonates
Stomach Ulcer
Gelatin
Double-Blind Method
Endoscopy
Osteoporosis
Capsules
Therapeutics
Placebos

Keywords

  • Bisphosphonate toxicity
  • Esophagitis
  • Osteoporosis
  • Pamidronate

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Lufkin, E. G., Argueta, R., Whitaker, M. D., Cameron, A. L., Wong, V. H., Egan, K. S., ... Riggs, B. L. (1994). Pamidronate: An unrecognized problem in gastrointestinal tolerability. Osteoporosis International, 4(6), 320-322. https://doi.org/10.1007/BF01622190

Pamidronate : An unrecognized problem in gastrointestinal tolerability. / Lufkin, E. G.; Argueta, R.; Whitaker, M. D.; Cameron, A. L.; Wong, V. H.; Egan, K. S.; O'Fallon, W. M.; Riggs, B. L.

In: Osteoporosis International, Vol. 4, No. 6, 11.1994, p. 320-322.

Research output: Contribution to journalArticle

Lufkin, EG, Argueta, R, Whitaker, MD, Cameron, AL, Wong, VH, Egan, KS, O'Fallon, WM & Riggs, BL 1994, 'Pamidronate: An unrecognized problem in gastrointestinal tolerability', Osteoporosis International, vol. 4, no. 6, pp. 320-322. https://doi.org/10.1007/BF01622190
Lufkin EG, Argueta R, Whitaker MD, Cameron AL, Wong VH, Egan KS et al. Pamidronate: An unrecognized problem in gastrointestinal tolerability. Osteoporosis International. 1994 Nov;4(6):320-322. https://doi.org/10.1007/BF01622190
Lufkin, E. G. ; Argueta, R. ; Whitaker, M. D. ; Cameron, A. L. ; Wong, V. H. ; Egan, K. S. ; O'Fallon, W. M. ; Riggs, B. L. / Pamidronate : An unrecognized problem in gastrointestinal tolerability. In: Osteoporosis International. 1994 ; Vol. 4, No. 6. pp. 320-322.
@article{91fef600f14d47ab85f93b17490b2528,
title = "Pamidronate: An unrecognized problem in gastrointestinal tolerability",
abstract = "Pamidronate (aminohydroxypropylidine bisphosphonate, APD) is an effective agent for treatment of Paget's disease of bone, and it has also been thought to be effective for treatment of osteoporosis. We desired to study a newer, time-release preparation of pamidronate, and carried out a placebo-controlled, double-masked study of postmenopausal osteoporosis. The original formulation was in a rapidly dissolving gelatin capsule. We encountered four episodes of esophagitis in 49 enrolled patients. We therefore discontinued treatment with this preparation and later began the study again using a standard tablet preparation. We encountered an additional case of erosive esophagitis in 1 patient of 40 receiving this tablet preparation. No patient was receiving concomitant medication which could cause esophagitis. Two of the patients gave a past history of hiatal hernia and 1 gave a history of gastric ulcer 27 years previously. The diagnosis of esophagitis was confirmed in all cases by endoscopy. Healing of the esophagitis promptly ensued after discontinuation of the pamidronate and the use of antacid medication.",
keywords = "Bisphosphonate toxicity, Esophagitis, Osteoporosis, Pamidronate",
author = "Lufkin, {E. G.} and R. Argueta and Whitaker, {M. D.} and Cameron, {A. L.} and Wong, {V. H.} and Egan, {K. S.} and O'Fallon, {W. M.} and Riggs, {B. L.}",
year = "1994",
month = "11",
doi = "10.1007/BF01622190",
language = "English (US)",
volume = "4",
pages = "320--322",
journal = "Osteoporosis International",
issn = "0937-941X",
publisher = "Springer London",
number = "6",

}

TY - JOUR

T1 - Pamidronate

T2 - An unrecognized problem in gastrointestinal tolerability

AU - Lufkin, E. G.

AU - Argueta, R.

AU - Whitaker, M. D.

AU - Cameron, A. L.

AU - Wong, V. H.

AU - Egan, K. S.

AU - O'Fallon, W. M.

AU - Riggs, B. L.

PY - 1994/11

Y1 - 1994/11

N2 - Pamidronate (aminohydroxypropylidine bisphosphonate, APD) is an effective agent for treatment of Paget's disease of bone, and it has also been thought to be effective for treatment of osteoporosis. We desired to study a newer, time-release preparation of pamidronate, and carried out a placebo-controlled, double-masked study of postmenopausal osteoporosis. The original formulation was in a rapidly dissolving gelatin capsule. We encountered four episodes of esophagitis in 49 enrolled patients. We therefore discontinued treatment with this preparation and later began the study again using a standard tablet preparation. We encountered an additional case of erosive esophagitis in 1 patient of 40 receiving this tablet preparation. No patient was receiving concomitant medication which could cause esophagitis. Two of the patients gave a past history of hiatal hernia and 1 gave a history of gastric ulcer 27 years previously. The diagnosis of esophagitis was confirmed in all cases by endoscopy. Healing of the esophagitis promptly ensued after discontinuation of the pamidronate and the use of antacid medication.

AB - Pamidronate (aminohydroxypropylidine bisphosphonate, APD) is an effective agent for treatment of Paget's disease of bone, and it has also been thought to be effective for treatment of osteoporosis. We desired to study a newer, time-release preparation of pamidronate, and carried out a placebo-controlled, double-masked study of postmenopausal osteoporosis. The original formulation was in a rapidly dissolving gelatin capsule. We encountered four episodes of esophagitis in 49 enrolled patients. We therefore discontinued treatment with this preparation and later began the study again using a standard tablet preparation. We encountered an additional case of erosive esophagitis in 1 patient of 40 receiving this tablet preparation. No patient was receiving concomitant medication which could cause esophagitis. Two of the patients gave a past history of hiatal hernia and 1 gave a history of gastric ulcer 27 years previously. The diagnosis of esophagitis was confirmed in all cases by endoscopy. Healing of the esophagitis promptly ensued after discontinuation of the pamidronate and the use of antacid medication.

KW - Bisphosphonate toxicity

KW - Esophagitis

KW - Osteoporosis

KW - Pamidronate

UR - http://www.scopus.com/inward/record.url?scp=0028606037&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028606037&partnerID=8YFLogxK

U2 - 10.1007/BF01622190

DO - 10.1007/BF01622190

M3 - Article

C2 - 7696825

AN - SCOPUS:0028606037

VL - 4

SP - 320

EP - 322

JO - Osteoporosis International

JF - Osteoporosis International

SN - 0937-941X

IS - 6

ER -